论文部分内容阅读
目的测定患者尿I型胶原交联氨基末端肽(uNTX)水平,评价其与骨转移瘤病情发展和疗效的关系。方法研究对象分为A、B、C三组。A组为正常成人组;B组为原发肿瘤组;C组为骨转移瘤组。分别检测3组uNTX水平及血清AKP活性和Ca2+浓度,C组治疗后10~12周进行uNTX的随访观察。结果C组uNTX水平显著高于A、B两组,骨转移瘤患者治疗前后uNTX水平也有显著性差异。结论uNTX水平与骨转移的发生呈正相关,uNTX敏感性高于血清AKP活性和Ca2+浓度,在鉴别骨转移瘤和监测病变进程中有预测价值,也是评价骨转移瘤患者疗效反应的早期客观指标之一。
Objective To determine the level of cross-linked amino-terminal peptide (uNTX) in patients with urinary type I collagen and evaluate its relationship with the development and efficacy of bone metastases. Methods The subjects were divided into three groups: A, B, and C. A group was normal adult group; B group was primary tumor group; C group was bone metastasis group. The levels of uNTX, serum AKP activity and Ca2+ concentration were detected in 3 groups. Follow-up observation of uNTX was performed 10 to 12 weeks after treatment in group C. Results The level of uNTX in group C was significantly higher than that in group A and B. There was also a significant difference in the level of uNTX before and after treatment in patients with bone metastases. Conclusion The level of uNTX is positively correlated with the occurrence of bone metastases. The sensitivity of uNTX is higher than that of serum AKP activity and Ca2+ concentration. It is of predictive value in the differential diagnosis of bone metastases and the monitoring of the progression of lesions. It is also an objective index to evaluate the response of patients with bone metastases. one.